REAL WORLD IMPACT OF RIFAXIMIN-Α USE IN HEPATIC ENCEPHALOPATHY PATIENTS WITH ADVANCED LIVER DISEASE OR CONTINUED ALCOHOL MISUSE: A POST-HOC ANALYSIS OF THE IMPRESS STUDY



This item was part of UEG Week 2017